Citius Posts Wider Loss in Fiscal Q3
Citius Pharmaceuticals (NASDAQ:CTXR), a late-stage biopharmaceutical company focused on developing and commercializing critical care therapies, reported its earnings for the fiscal third quarter of 2025 on August 12, 2025. The quarter featured no revenue, and a net loss per share of ($0.80) (GAAP), falling short of the consensus analyst estimate of ($0.51) (GAAP). Operating expenses (GAAP) declined from last year, but liquidity remains tight even after capital raises. The quarter highlighted both notable progress towards bringing its first approved drug to market and persistent financial risks as it transitions into a commercial-stage company.
Source: Analyst estimates for the quarter provided by FactSet.
The company specializes in developing and commercializing critical care therapies. Its lead asset, LYMPHIR, is a targeted immunotherapy for cutaneous T-cell lymphoma, a type of cancer that affects the skin’s T cells. The company’s primary focus in recent quarters has been advancing LYMPHIR from development to full commercialization within the United States, as well as progressing other pipeline candidates including its antibiotic lock solution, Mino-Lok, and the treatment CITI-002 (Halo-Lido).
Source Fool.com
